Clinical Trial Update: Investigation of Optimal Dosing Conditions for a Long Acting GLP-1 Analogue in Healthy Male Subjects [Phase 1]

View source ↗

Summary

Phase 1 study by Novo Nordisk evaluated optimal dosing for a long-acting GLP-1 receptor agonist in healthy male volunteers; the trial status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Long-acting GLP-1 receptor agonist

Snippet

Sponsor: Novo Nordisk A/S | Conditions: Diabetes, Diabetes Mellitus, Type 2 | Phase 1 | Status: COMPLETED